Eli Lilly’s direct drug sales alone may not upend the industry, but others could follow suit

[ad_1] Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs,…

You Can Now Get Weight-Loss Drugs Right From Eli Lilly

[ad_1] Eli Lilly started a new online service offering telehealth prescriptions and direct home delivery of its new anti-obesity drug Zepbound, an unusual move into the drug supply chain by…

Essay | What Went Right in 2023

[ad_1] According to most polls, Americans are ending the year in a sour mood. Trust in all public institutions, ranging from the government to the Supreme Court to the media…

The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead

[ad_1] George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market.  The drugs…

Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects

[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the…

Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook

[ad_1] Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. Cristina Arias | Cover | Getty Images Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that…

As Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with data

[ad_1] Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. In the first…

Ozempic Boom Is an Opportunity for Health Insurers

[ad_1] You would think a new class of high-price weight loss drugs taken by millions of Americans would be a problem for health insurers. After all, they ultimately foot the…

WSJ News Exclusive | The Next Hot Obesity Drug Won’t Be Approved for Years. Online Sellers Hawk It Anyway.

[ad_1] Eli Lilly’s retatrutide will be in clinical trials for the next three years, but knockoff versions already abound. [ad_2] Source link